Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM
-
Number of holders
-
133
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+2.98M
-
Total reported value, excl. options
-
$606M
-
Value change
-
+$53.6M
-
Put/Call ratio
-
1.01
-
Number of buys
-
65
-
Number of sells
-
-53
-
Price
-
$17.37
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2023
154 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q3 2023.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 133 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
.
Largest 10 shareholders include BlackRock Inc. (3.12M shares), Rubric Capital Management LP (3.08M shares), VANGUARD GROUP INC (2.96M shares), BAKER BROS. ADVISORS LP (2.81M shares), Fairmount Funds Management LLC (2.47M shares), STATE STREET CORP (1.76M shares), Pictet Asset Management Holding SA (1.6M shares), MORGAN STANLEY (1.49M shares), GOLDMAN SACHS GROUP INC (866K shares), and ArrowMark Colorado Holdings LLC (760K shares).
This table shows the top 133 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.